<code id='D8A445B5F1'></code><style id='D8A445B5F1'></style>
    • <acronym id='D8A445B5F1'></acronym>
      <center id='D8A445B5F1'><center id='D8A445B5F1'><tfoot id='D8A445B5F1'></tfoot></center><abbr id='D8A445B5F1'><dir id='D8A445B5F1'><tfoot id='D8A445B5F1'></tfoot><noframes id='D8A445B5F1'>

    • <optgroup id='D8A445B5F1'><strike id='D8A445B5F1'><sup id='D8A445B5F1'></sup></strike><code id='D8A445B5F1'></code></optgroup>
        1. <b id='D8A445B5F1'><label id='D8A445B5F1'><select id='D8A445B5F1'><dt id='D8A445B5F1'><span id='D8A445B5F1'></span></dt></select></label></b><u id='D8A445B5F1'></u>
          <i id='D8A445B5F1'><strike id='D8A445B5F1'><tt id='D8A445B5F1'><pre id='D8A445B5F1'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:knowledge    Page View:52
          Stock exchange
          Drew Angerer/Getty Images

          Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

          In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

          advertisement

          Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Inside the rise of 'mukbang' eating videos
          Inside the rise of 'mukbang' eating videos

          8:11YouTuberBethanyGaskinfilmsa"mukbang"video.ABCNewsTrishaPaytascaughtontothe'mukbang'tre

          read more
          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more

          White House pharmacy plagued with problems, investigation finds

          SamuelCorum/GettyImagesThere’sapharmacyintheWhiteHouse—or,atleast,there’sasignthatsays“Pharmacy,”tho